Clal Biotechnology | CBI - Operating Profit


Clal Biotechnology reported ILS-1.74M in Operating Profit for its fiscal quarter ending in December of 2022.





Operating Profit Change Date
Arca Biopharma USD -34.43M 326K Dec/2025
aTyr Pharma USD 24.47M 51.21M Dec/2025
Bio Path USD -488K 4.07M Sep/2025
Brainstorm Cell Therapeutics USD -2.24M 197K Dec/2025
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD 56.04M 63.93M Dec/2025
Immunic USD -25.73M 2.91M Sep/2024
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
RedHill Biopharma USD -4.22M 1.8M Jun/2024
TherapeuticsMD USD -1.18M 40K Jun/2024